Life Sciences + Health
Leaders in Medical Translation in 250+ Languages
Evaluating Geographical Clinical Trial Trends with Dr. Vladimir Misik
In our fourth podcast episode, CSOFT CEO Ms. Shunee Yee and special guest Dr. Vladimir Misik sat down to discuss the shifting clinical trial landscape and future predictions for industry investment and market share.
MACHINE TRANSLATION FOR THE LIFE SCIENCE INDUSTRIES: THE MYTH AND THE TRUTH
Our Newest White Paper explores how the rapid development of AI technology and machine learning have provided the translation industry with new capabilities in machine translation (MT), particularly for the life science sector. Learn about the different kinds of MT as well as its potential benefits and limitations across the life sciences industries in facilitating cheaper and faster turnaround times for translation projects, without sacrificing quality.
Chemo Side Effects: A Global Challenge for
Advancements in global medicine and drug development are essential to improving treatment options that reduce adverse side effects for patients receiving chemotherapy.
FDA Approves Oyster Point First Nasal Spray for Dry Eyes
The US Food and Drug Administration (FDA) has approved Oyster Point’s nasal spray, Tyrvaya, the first nasal spray to treat chronic dry eye disease, helping around 38 million patients who suffer from the disease in the US.
We are dedicated to industry-standard knowledge and quality
Helping You Globalize the Right Way
CSOFT’s experienced and dedicated global regulatory submission specialists help companies comply with these demanding multilingual documentation requirements for submissions while providing the highest linguistic quality
We can help you attain the appropriate, accurate, and sustainable compliance required throughout the entire submission process. We ensure our clients receive the necessary certifications to successfully enter emerging markets.
Medical Translation with a Focus on Precision
Our translation solutions are intended for document types relating to every stage of product development life cycle.
Quality in translation is extremely important, but within the life sciences industry, incorrect translations could literally be life threatening. We use industry-standard processes, however, we also offer flexibility for each customer to allow for their companies’ success, no matter the process.
Industries We Serve
Who We Are
CSOFT Health Sciences, leaders in medical translation, provides end-to-end medical translations for all phases of the product lifecycle, from pre-clinical to post-launch. We also specialize in market access consulting, medical writing, and CTD/eCTD submissions with the FDA, EMA, and NMPA.
Our operations are compliant with ISO 17100 and certified in ISO 9001:2015 and ISO 13485:2016, ensuring our customized solutions meet the rigorous regulatory requirements of global submissions.
The Power of Linguistic Expertise
Right Tools. Right Resources
Tools we use
We use a full range of CAT tools including Trados, MemoQ, Transifex, Smartling, and WordServer and translate all document types, including .ai, .doc, .pdf, .ppt, .xlx, .css, .php, .html, .xml, .mml, .txt, .mpg, .mov, .zip, .psd, and more.
Linguists we hire
Our native in-country subject-matter experts with at least 7 years’ experience go through a rigorous certification process and are guided with customer experience surveys
CSOFT works extensively with medical professionals who are dedicated to prevalent therapeutic areas
Start Your Global Journey
The Knowledge Vault
Stay in the know
For many years, CSOFT has been supporting the life science industries as they continue to grow. We are dedicated to providing the highest-quality services to our clients, while making sure they have access to different policies and up-to-date information. As a medical communications company, we are taking the initiative to promote and increase awareness in the science community and to every individual.
Novavax, a biotechnology company committed to development and bringing to market next-generation vaccines for critical infectious diseases, announced that it has finalized its ongoing regulatory submission to the U.K. Medicines and Healthcare products Regulatory...
Solasia Pharma K.K (Salasia) and Nippon Kayaku (Nippon) have announced their joint license agreement for marketing rights for darinaparsin (SP-02) in Japan. Drug candidate developed by Salasia, darinaparsin, aims to treat relapsed or refractory peripheral T-cell...
Resilia Pharmaceuticals has been granted the rights to manufacture, commercialize and sell Solace™ Eczema Cream, a medical device, as an OTC (over the counter) product in the United States. Signing the agreement with Pelle Ventures, the deal will make the cream more...
Advancements in global medicine and specialist care are essential to improving quality of life, treatment options, and survival rates for those with a cancer diagnosis, as well as mitigating the side effects that come with receiving those treatments. Recently, the US...
The US Food and Drug Administration (FDA) has given Norwegian pharmaceutical company Ultimovacs ASA Fast Track designation for its experimental product, UV1, as a supplementary therapy to either pembrolizumab or ipilimumab for the treatment of unresectable or...
The US Food and Drug administration (FDA) has given approvals to Moderna and Johnson & Johnson (J&J) to authorize boosters. By using a mix and match approach, the FDA has authorized the boosters for all populations eligible to receive one under the emergency...